GLG News by Neonatal-Perinatal Physicians (US)

Strattera has been approved for "maintenance treatment" for ADHD, however this probably changes nothing for prescribers or patients.  Those who are on it will continue to take it, but no one will be changing to Strattera because of this new classification.

While this is new data from an 18 month study, the common practice already is to "stick with what works." Thus, if a child is started on Strattera (or another ADHD medication) and has positive results, the physician will most likely continue that drug.

Although just a press release, the itself study is interesting. The attempt to modify the symptoms of ADHD by affecting neurotransmitter release or reuptake is not new, but this is an attempt to do so via a novel receptor pathway.

we really have had little luck with straterra in  our office.  Even at high  doses,  the drug rarely does the trick

the vaccines may be similar, but I'll stick with the Merck product

what goes up must come down.  This speculation in oil has happened many times during my lifetime and it is the same with all commodites (remember the holland tulips).  Yes, many have and will make fortunes in commoditiy trades, but in the end the real intrinsic value comes through.  When...

Physician ranking systems will certainly be a part of medical practice. But the real utility is not going to be in allowing patients to choose the "best" doctors--that will perpetuate the fallacy of drawing conclusions about a specific case from the general data. And the ability of this information...

Menveo appears to have some statistical advantages over the currently available product, Menactra (sanofi aventis.) Whether the higher antibody levels translate into better or more lasting protection remains to be seen. Given recent FDA action approving meningococcal vaccine for younger pediatric age...

-Rotateq and Rotarix are the only two approved rotavirus vaccines in the US.  It's unclear how Rotarix will be priced, and since it is a 2-dose series vs. Rotateq's 3-dose series, the cost will be very important. -However, there are other factors as well, such as Merck being first to market...

The proposed PTO rules, while logical on the surface, suffer from the all too common defect of over-generalization. In patent applications, as in so many other fields, there is usually not a one size fits all approach.